OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more
OliX PharmaceuticalsInc (226950) - Net Assets
Latest net assets as of September 2025: ₩142.56 Billion KRW
Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has net assets worth ₩142.56 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩186.58 Billion) and total liabilities (₩44.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩142.56 Billion |
| % of Total Assets | 76.41% |
| Annual Growth Rate | 4.49% |
| 5-Year Change | -60.59% |
| 10-Year Change | N/A |
| Growth Volatility | 111.96 |
OliX PharmaceuticalsInc - Net Assets Trend (2016–2024)
This chart illustrates how OliX PharmaceuticalsInc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OliX PharmaceuticalsInc (2016–2024)
The table below shows the annual net assets of OliX PharmaceuticalsInc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩17.85 Billion | -64.54% |
| 2023-12-31 | ₩50.34 Billion | -23.63% |
| 2022-12-31 | ₩65.91 Billion | +255.85% |
| 2021-12-31 | ₩18.52 Billion | -59.10% |
| 2020-12-31 | ₩45.29 Billion | +8.34% |
| 2019-12-31 | ₩41.80 Billion | -23.92% |
| 2018-12-31 | ₩54.94 Billion | +194.16% |
| 2017-12-31 | ₩18.68 Billion | +48.73% |
| 2016-12-31 | ₩12.56 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to OliX PharmaceuticalsInc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15561449651000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩9.23 Billion | 51.71% |
| Other Components | ₩171.39 Billion | 960.20% |
| Total Equity | ₩17.85 Billion | 100.00% |
OliX PharmaceuticalsInc Competitors by Market Cap
The table below lists competitors of OliX PharmaceuticalsInc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oberbank AG
VI:OBS
|
$2.11 Billion |
|
Deciphera Pharmaceuticals Inc
F:D05
|
$2.11 Billion |
|
MORGAN SINDALL GRP LS-05
F:0KN
|
$2.11 Billion |
|
Hui Lyu Ecological Technology Groups Co Ltd
SHE:001267
|
$2.11 Billion |
|
Indra Sistemas S.A
OTCGREY:ISMAF
|
$2.11 Billion |
|
Sumitomo Rubber Industries Ltd
F:108
|
$2.11 Billion |
|
WuXi XDC Cayman Inc.
F:L74
|
$2.11 Billion |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
$2.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OliX PharmaceuticalsInc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 49,854,507,610 to 17,848,889,860, a change of -32,005,617,750 (-64.2%).
- Net loss of 40,658,699,600 reduced equity.
- Other factors increased equity by 8,653,081,850.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-40.66 Billion | -227.79% |
| Other Changes | ₩8.65 Billion | +48.48% |
| Total Change | ₩- | -64.20% |
Book Value vs Market Value Analysis
This analysis compares OliX PharmaceuticalsInc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 192.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 134.52x to 192.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1387.16 | ₩186600.00 | x |
| 2017-12-31 | ₩1793.90 | ₩186600.00 | x |
| 2018-12-31 | ₩4223.45 | ₩186600.00 | x |
| 2019-12-31 | ₩3200.42 | ₩186600.00 | x |
| 2020-12-31 | ₩3344.07 | ₩186600.00 | x |
| 2021-12-31 | ₩1351.59 | ₩186600.00 | x |
| 2022-12-31 | ₩4809.65 | ₩186600.00 | x |
| 2023-12-31 | ₩3114.01 | ₩186600.00 | x |
| 2024-12-31 | ₩966.92 | ₩186600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OliX PharmaceuticalsInc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -227.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -716.18%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 3.99x
- Recent ROE (-227.79%) is below the historical average (-67.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -29.11% | -932.79% | 0.03x | 1.21x | ₩-4.91 Billion |
| 2017 | -27.65% | -2116.65% | 0.01x | 1.16x | ₩-7.03 Billion |
| 2018 | -14.09% | -2563.58% | 0.01x | 1.01x | ₩-13.24 Billion |
| 2019 | -34.34% | -1269.79% | 0.03x | 1.08x | ₩-18.53 Billion |
| 2020 | -42.81% | -783.44% | 0.03x | 1.74x | ₩-23.91 Billion |
| 2021 | -160.44% | -808.70% | 0.04x | 4.68x | ₩-31.57 Billion |
| 2022 | -29.58% | -209.17% | 0.07x | 2.01x | ₩-26.09 Billion |
| 2023 | -38.31% | -111.94% | 0.17x | 2.06x | ₩-24.09 Billion |
| 2024 | -227.79% | -716.18% | 0.08x | 3.99x | ₩-42.44 Billion |
Industry Comparison
This section compares OliX PharmaceuticalsInc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OliX PharmaceuticalsInc (226950) | ₩142.56 Billion | -29.11% | 0.31x | $2.11 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |